0000000000427186

AUTHOR

Liang Shen

showing 5 related works from this author

79TiP A phase II/III, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary trac…

2020

Cisplatinmedicine.medical_specialtyBiliary tract cancerbusiness.industryPlacebo-controlled studyHematologyGastroenterologyGemcitabineFirst line treatmentOncologyInternal medicinemedicinebusinessmedicine.drugAnnals of Oncology
researchProduct

P-34 The randomized, double-blind, placebo-controlled phase 3 trial KEYNOTE-975: Pembrolizumab vs placebo in patients with esophageal carcinoma recei…

2020

medicine.medical_specialtybusiness.industryHematologyDefinitive chemoradiotherapyPembrolizumabPlacebomedicine.diseaseGastroenterologyDouble blindOncologyInternal medicineCarcinomaMedicineIn patientbusinessAnnals of Oncology
researchProduct

LBA7 Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophagea…

2021

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentFirst lineEsophageal adenocarcinomaCancerIpilimumabHematologyAdvanced gastric cancerGastroesophageal Junctionmedicine.diseaseOncologyInternal medicinemedicineNivolumabbusinessmedicine.drugAnnals of Oncology
researchProduct

P-138 Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy in first-line therapy of advanced/metasta…

2021

OncologyChemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentMargetuximabAnti pd 1CancerHematologymedicine.diseaseGastroesophageal JunctionFirst line therapyOncologyInternal medicinemedicinebusinessAnnals of Oncology
researchProduct

P-342 Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ g…

2020

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentMargetuximabAnti pd 1CancerHematologyGastroesophageal Junctionmedicine.diseaseFirst line therapyOncologyInternal medicinemedicinebusinessAnnals of Oncology
researchProduct